Bli medlem
Bli medlem

Du är här


Hansa Medical: Hansa Medical to present IdeS at the World Orphan Drug Congress USA, April 24 in Washington D.C.

The presentation focusing on Hansa Medical's lead drug-candidate IdeS'
capacity for desensitization prior to kidney transplantation is
scheduled for 3:15 pm on April 24.

The World Orphan Drug Congress USA will be held on April 23-25 at the
Grand Hyatt Washington, Washington D.C. For more information about
the event please visit:

The company presentation's emphasize will be on its lead
drug-candidate IdeS, IdeS' recent clinical Phase I results and IdeS'
forthcoming Phase II studies in 2014.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of
innovative pharmaceuticals and diagnostic methods for the benefit of
patients with serious and rare inflammatory diseases. The portfolio
includes a marketed diagnostic product, a drug candidate in clinical
development, and a preclinical research project. Major shareholders
are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa
Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic
AB is the company's Certified Adviser.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.